When was Valirx founded?

Valirx was founded in 2000 and raised its 1st funding round 13 years after it was founded.

Where is Valirx located?

Valirx is headquartered in London, United Kingdom.

Who is the current CEO of Valirx?

Satu Vainikka and Suzy Dilly s of Valirx.

How many employees does Valirx have?

As of Jul 31, 2026, the latest employee count at Valirx is 11.

Is Valirx a funded company?

Valirx is a funded company, having raised an undisclosed amount across 11 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Dec 27, 2013.

When was the latest funding round of Valirx?

Valirx's latest funding was a $***** Post IPO round on Jun 13, 2019, with participation from 0 investor. Its primary sector is Genomics. In United Kingdom, the Genomics sector has seen $70.2M in funding in 2026 to date.

Where does Valirx rank among its competitors?

Valirx ranks 19th amongst 231 active competitors, of which 75 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was GRAIL, which secured $110M in Jun, 2026.

Who are the top competitors of Valirx?

Valirx's top competitors include Seer, Tango Therapeutics and Exact Sciences. Among them, GRAIL secured the most recent funding round in June, 2026.

Valirx - 2026 Company Profile, Team, Funding, Competitors & Financials

Valirx is a public company based in London (United Kingdom), founded in 2000. It operates as a Developer of novel technologies and products in oncology therapeutics and diagnostics. Valirx has raised an undisclosed amount in funding. The company has 231 active competitors, including 75 funded and 38 that have exited. Its top competitors include companies like Seer, Tango Therapeutics and Exact Sciences.

Company Details

Developer of novel technologies and products in oncology therapeutics and diagnostics. Its lead programs include VAL201 for the treatment of prostate cancer and VAL401 for lung cancer. Its other proprietaries include GeneICE (VAL101), a technology that enables selective silencing of the rebellion, preventing the activity from the rebellious gene; GeneICE – Bcl-2, a new therapeutic drug that targets and switch off the gene that expresses Bcl-2 and NAV3 cancer screening test that indicates the onset of malignancy or tumour formation.

Website: www.valirx.com
Email ID: *****@valirx.com

Key Metrics

Founded Year

2000

Location

London, United Kingdom

Stage

Public

Latest Funding Round

Post IPO, Jun 13, 2019, $*****

Ranked

19^th among 231 active competitors

Employee Count

11 as on Jul 31, 2026

Investment & Acquisitions

TuHURA Biosciences

Similar Companies

Seer & 312 more

Exit Details

Public

View Valirx's full profile

Valirx is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Valirx Plc CIN: 3916791 , Germany, Active	Jan 25, 2000	-	7 (As on Dec 31, 2021)

Valirx got listed on Oct 03, 2006.

Click here to take a look at Valirx's IPO in detail

Valirx has raised funding over 11 rounds. Its first funding round was on Dec 27, 2013.

Here is the list of recent funding rounds of Valirx:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 13, 2019	1617267	Post IPO	1311798	2886743	9631777	3863213
Dec 18, 2018	3612575	Post IPO	8991930	7923755	3647592	3957471
Dec 2018	3368138	Post IPO	6804490	7092921	7162409	8291582

Access funding benchmarks and valuations. Sign up today!

View details of Valirx's funding rounds and investors

Valirx's employee count trend

Valirx has 11 employees as of Jul 26. Here is Valirx's employee count trend over the years:

Uncover Valirx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Valirx include Seer, Tango Therapeutics and Exact Sciences. Here is the list of Top 10 competitors of Valirx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Seer 2017, San Francisco (United States), Public	Developer of proteomics platform for early detection of cancer and neurological diseases	$128M	aMoon, Fidelity Investments & 15 others	72/100
2nd	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	71/100
3rd	Exact Sciences 1995, Madison (United States), Acquired	Provider of non-invasive molecular diagnostic testing solutions for cancer	-	Petrillo Capital, Back Bay Group & 8 others	71/100
4th	GRAIL 2016, Menlo Park (United States), Public	Developer of a screening platform for circulating tumor DNA to detect cancer	$2B	Arch Venture Partners, Hillhouse & 52 others	69/100
5th	UDX 2012, Seville (Spain), Series C	Developer of non-invasive blood-based diagnostics for cancer	$105M	Quest Diagnostics, Olympus & 6 others	67/100
6th	Maze Therapeutics 2018, Redwood City (United States), Public	Developer of genetic bio-markers in neurological, metabolic, and renal diseases	$496M	Matrix Capital Management, Frazier Life Sciences ... & 21 others	66/100
7th	Metabolon 2000, Morrisville (United States), Series H	Provider of solutions for biomarker discovery, diagnostic tests and personalized medicine	$166M	Sevin Rosen, Syngenta Group Ventures & 17 others	66/100
8th	Lexicon Pharmaceuticals 1995, The Woodlands (United States), Public	Developer of small molecule drugs for diffrent health diseases	-	Bay City Capital, New Enterprise Associates ... & 3 others	64/100
9th	NeoGenomics 2002, Fort Myers (United States), Public	Provider of cancer genetic diagnostic services	-	Ranger Investments, Aspen Capital & 1 others	63/100
10th	Wobble Genomics 2020, Edinburgh (United Kingdom), Series A	Provider of a platform for discovery of nucleic acid biomarkers	$12.5M	Mercia, Eos Advisory & 35 others	62/100
19th	Valirx 2000, London (United Kingdom), Public	Developer of novel technologies and products in oncology therapeutics and diagnostics	-	-	53/100